8-methoxy-2-propionamidotetralin: enhances sperm hyperactivation via the MT1 receptor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5170952 |
| CHEMBL ID | 99377 |
| CHEBI ID | 111166 |
| SCHEMBL ID | 55299 |
| MeSH ID | M0527904 |
| Synonym |
|---|
| CHEMBL99377 , |
| n-(8-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide |
| bdbm50045843 |
| n-(8-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propionamide |
| 8-m-pdot |
| HMS3267A12 |
| BRD-A07232941-001-01-9 |
| PDSP2_001797 |
| PDSP1_001814 |
| NCGC00024954-02 |
| CHEBI:111166 |
| L005063 |
| 134865-70-6 |
| SCHEMBL55299 |
| AKOS022488635 |
| m-pdot, 8- |
| ah 002 |
| 8-methoxy-2-propionamidotetralin |
| Q27190620 |
| SR-01000597468-1 |
| sr-01000597468 |
| FT-0774238 |
| HMS3676A17 |
| HY-101358 |
| CS-0021215 |
| ah-002 |
| HMS3412A17 |
| MS-23343 |
| Class | Description |
|---|---|
| tetralins | Compounds containing a tetralin skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 1.1220 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 28.1838 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 0.5973 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 0.2239 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Melatonin receptor type 1A | Homo sapiens (human) | IC50 (µMol) | 0.0005 | 0.0000 | 0.0640 | 1.0200 | AID165366 |
| Melatonin receptor type 1B | Homo sapiens (human) | IC50 (µMol) | 0.0005 | 0.0000 | 0.3489 | 4.0000 | AID165366 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protein binding | Melatonin receptor type 1A | Homo sapiens (human) |
| melatonin receptor activity | Melatonin receptor type 1A | Homo sapiens (human) |
| hormone binding | Melatonin receptor type 1A | Homo sapiens (human) |
| organic cyclic compound binding | Melatonin receptor type 1A | Homo sapiens (human) |
| G protein-coupled receptor activity | Melatonin receptor type 1A | Homo sapiens (human) |
| protein binding | Melatonin receptor type 1B | Homo sapiens (human) |
| melatonin receptor activity | Melatonin receptor type 1B | Homo sapiens (human) |
| G protein-coupled receptor activity | Melatonin receptor type 1B | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Melatonin receptor type 1A | Homo sapiens (human) |
| receptor complex | Melatonin receptor type 1A | Homo sapiens (human) |
| plasma membrane | Melatonin receptor type 1A | Homo sapiens (human) |
| plasma membrane | Melatonin receptor type 1B | Homo sapiens (human) |
| synapse | Melatonin receptor type 1B | Homo sapiens (human) |
| plasma membrane | Melatonin receptor type 1B | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID165366 | Inhibition of 2-[125I]iodomelatonin stimulated calcium dependent dopamine release from the rabbit retina. | 1993 | Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20 | 2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents. |
| AID107543 | Binding affinity to compete for 2-[125I]iodomelatonin binding to chicken retinal membranes | 1993 | Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20 | 2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents. |
| AID107400 | Negative logarithm of relative affinity (pRA) towards melatonin receptor (relative to N-acetyl-5-methoxytryptamine (aMT)) | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20 | Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study. |
| AID107545 | Relative binding affinity to chicken retinal membranes compared to 2-[125I]iodomelatonin. | 1993 | Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20 | 2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents. |
| AID165408 | Relative potency of inhibition of calcium-dependent release of [3H]dopamine from rabbit retina caused by 2-[125I]iodomelatonin. | 1993 | Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20 | 2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.86) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||